MedTrace Logo

DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours

NCT05582850 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2026-05-12

Study results available
· View outcomes & findings →

Summary

This is a Phase 1, multicentre, open-label, dose-escalation study to determine a recommended phase 2 dose (RP2D) of DT-9081, followed by an expansion study of DT-9081 in participants with advanced, recurrent or metastatic solid tumours

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

DT-9081 - dose escalation

Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.

DRUG

DT-9081 - expansion

A homogeneous patient population will receive DT-9081 at up to 3 dose levels.

Sponsors & Collaborators

  • Domain Therapeutics SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-24
Primary Completion
2025-04-08
Completion
2025-04-08

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05582850 on ClinicalTrials.gov